Sab biotherapeutics advancing pipeline and expands into treatment for c. diff. as dod contract winds down

Sioux falls, s.d., aug. 09, 2022 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), (sab), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, announced that it will be discontinuing its work with the u.s. department of defense (dod) under a prototype research and development agreement. the agreement, which was awarded in the summer of 2019, underwent significant modifications as a result of the covid-19 pandemic, and the government's evolving requirements no longer align with the goals of the agreement as originally contemplated. as part of the closeout process, sab and the dod will engage in a comprehensive negotiation to address all open items under the agreement, which is expected to include a multi-million-dollar payment to sab.
SABS Ratings Summary
SABS Quant Ranking